First Manhattan Co. (“FMC”), an owner-managed and operated investment
advisory firm and the owner of approximately 9.9 percent of the
outstanding shares of VIVUS, Inc. (“Vivus”) VVUS, today urged
Vivus shareholders to consider three key facts as they make the
important choice that will determine the future of their investment in
Vivus.
Fact I: The centralized procedure is the
best pathway for Qsymia's E.U. approval
Vivus originally attempted to gain E.U. approval through the centralized
procedure, but it failed. The centralized procedure is currently the
only pathway that large pharma uses for E.U. approval of blockbuster
drugs according to FMC's consultants. The primary reason for choosing
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in